Page 274 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 274
Viral Hepatitis: Hepatitis C - Clinical (Therapy) (Cont.)
YI P0884 INTERFERON AND RIBAVIRIN-FREE THERAPY WITH
SOFOSBUVIR AND DACLATASVIR IN A REAL-LIFE COHORT
OF DIFFICULT-TO-TREAT HIV/HCV-COINFECTED
PATIENTS WITH AND WITHOUT PORTAL HYPERTENSION
Mattias Mandorfer, Sebastian Steiner*, Philipp Schwabl,
Maximilian C. Aichelburg, Katharina Grabmeier-Pfistershammer,
Armin Rieger, Michael Trauner, Thomas Reiberger,
Markus Peck-Radosavljevic, Austria
YI P0885 MOST PATIENTS OF HEPATITIS C VIRUS INFECTION IN
INDIA PRESENT LATE FOR ANTIVIRAL TREATMENT:
AN EPIDEMIOLOGICAL STUDY FROM A NORTH INDIAN
CENTER
Varun Gupta*, Ashish Kumar, Praveen Sharma, Anil Arora, India
P0886 EFFICACY AND SAFETY OF GRAZOPREVIR/ELBASVIR
+/- RBV FOR 12 WEEKS IN PATIENTS WITH HCV G1 OR G4
ePOSTERS INFECTION WHO PREVIOUSLY FAILED PEGINTERFERON/
RBV: C-EDGE TREATMENT-EXPERIENCED TRIAL
Paul Kwo*, Ed Gane, Cheng-Yuan Peng, Brian Pearlman, John Vireling,
Lawrence Serfaty, Maria Buti, Stephen Shafran, Paul Stryszak,
Li Lin, Jacqueline Gress, Michael Robertson, Janice Wahl, Eliav Barr,
Barbara Haber, The United States
P0887 C-EDGE CO-INFECTED: PHASE 3 STUDY OF
GRAZOPREVIR/ELBASVIR IN PATIENTS WITH HCV/HIV
Jurgen K. Rockstroh*, Mark Nelson, Christine Katlama, Jay Lalezari,
Josep Mallolas, Mark Bloch, Gail Matthews, Michael Saag,
Philippe Zamor, Chloe Orkin, Jacqueline Gress, Stephanie Klopfer,
Heather Platt, Michael Robertson, Mark Sulkowski, Germany
P1353 A SINGLE TABLET REGIMEN OF LEDIPASVIR/SOFOSBUVIR
FOR 12 WEEKS IN HCV GENOTYPE 1 OR 4 INFECTED
PATIENTS WITH HIV-1 CO-INFECTION: THE PHASE 3 ION-4
STUDY
Curtis Cooper*, Susanna Naggie, Michael Saag, Jenny Yang,
Luisa Stamm, Philip Pang, John McHutchison, Douglas Dieterich,
Mark Sulkowski, Canada
274 The International Liver Congress™ 2015 • ILC Programme
YI P0884 INTERFERON AND RIBAVIRIN-FREE THERAPY WITH
SOFOSBUVIR AND DACLATASVIR IN A REAL-LIFE COHORT
OF DIFFICULT-TO-TREAT HIV/HCV-COINFECTED
PATIENTS WITH AND WITHOUT PORTAL HYPERTENSION
Mattias Mandorfer, Sebastian Steiner*, Philipp Schwabl,
Maximilian C. Aichelburg, Katharina Grabmeier-Pfistershammer,
Armin Rieger, Michael Trauner, Thomas Reiberger,
Markus Peck-Radosavljevic, Austria
YI P0885 MOST PATIENTS OF HEPATITIS C VIRUS INFECTION IN
INDIA PRESENT LATE FOR ANTIVIRAL TREATMENT:
AN EPIDEMIOLOGICAL STUDY FROM A NORTH INDIAN
CENTER
Varun Gupta*, Ashish Kumar, Praveen Sharma, Anil Arora, India
P0886 EFFICACY AND SAFETY OF GRAZOPREVIR/ELBASVIR
+/- RBV FOR 12 WEEKS IN PATIENTS WITH HCV G1 OR G4
ePOSTERS INFECTION WHO PREVIOUSLY FAILED PEGINTERFERON/
RBV: C-EDGE TREATMENT-EXPERIENCED TRIAL
Paul Kwo*, Ed Gane, Cheng-Yuan Peng, Brian Pearlman, John Vireling,
Lawrence Serfaty, Maria Buti, Stephen Shafran, Paul Stryszak,
Li Lin, Jacqueline Gress, Michael Robertson, Janice Wahl, Eliav Barr,
Barbara Haber, The United States
P0887 C-EDGE CO-INFECTED: PHASE 3 STUDY OF
GRAZOPREVIR/ELBASVIR IN PATIENTS WITH HCV/HIV
Jurgen K. Rockstroh*, Mark Nelson, Christine Katlama, Jay Lalezari,
Josep Mallolas, Mark Bloch, Gail Matthews, Michael Saag,
Philippe Zamor, Chloe Orkin, Jacqueline Gress, Stephanie Klopfer,
Heather Platt, Michael Robertson, Mark Sulkowski, Germany
P1353 A SINGLE TABLET REGIMEN OF LEDIPASVIR/SOFOSBUVIR
FOR 12 WEEKS IN HCV GENOTYPE 1 OR 4 INFECTED
PATIENTS WITH HIV-1 CO-INFECTION: THE PHASE 3 ION-4
STUDY
Curtis Cooper*, Susanna Naggie, Michael Saag, Jenny Yang,
Luisa Stamm, Philip Pang, John McHutchison, Douglas Dieterich,
Mark Sulkowski, Canada
274 The International Liver Congress™ 2015 • ILC Programme
